TABLE 3.
Group | Vaccine antigen | ELISA titer
|
Neutralization titer (IC90)a
|
||||||
---|---|---|---|---|---|---|---|---|---|
CD4
|
gp120
|
MN
|
1357-0b
|
||||||
Undepleted | Depleted | Undepleted | Depleted | Undepleted | Depleted | Undepleted | Depleted | ||
1 | gp120 (DNA) | 3,200 | 3,200 | 100,000 | 100,000 | 80 | 46 | 10 | <46 |
1,600 | 1,600 | 400,000 | 400,000 | 160 | 46 | <10 | <46 | ||
1,600 | 1,600 | 50,000 | 50,000 | <10 | <40 | 20 | <40 | ||
6,400 | 6,400 | 400,000 | 400,000 | 40 | 44 | <10 | <44 | ||
2 | gp120-CD4D12 (DNA) | 300,000 | 1,000 | 400,000 | 400,000 | >1,280 | 51 | 160 | <51 |
1,638,400 | 1,000 | 100,000 | 100,000 | 320 | <57 | 160 | <57 | ||
6,553,600 | 1,000 | 100,000 | 100,000 | 640 | <67 | 320 | <67 | ||
1,638,400 | 1,000 | 100,000 | 100,000 | 160 | <48 | 20 | <48 |
IC90, 90% inhibitory concentration, expressed as the reciprocal of the serum dilution in which 90% or more of the viral antigen production was inhibited relative to production in untreated viral growth control wells.
CCR5-utilizing primary isolate.